Physicians have a lot going on. Between the pressures of clinical and administrative responsibilities, sometimes the only way to keep everything together is with a to-do list. Unfortunately, it can often feel as though some items never come off that list. Often, the bigger a project sounds, the more likely it is to sit on…
The FTC issued a Final Rule that banned non-compete agreements, but the rule was recently halted by a nationwide injunction from a federal court in Texas.
After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.
The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.
In light of new challenges to individuals’ reproductive rights and the known challenges of clinical management of rheumatic disease patients during pregnancy, we review the current state of reproductive rheumatology and the management of patients with rheumatic disease during pregnancy.
NEW YORK, Dec 17 (Reuters)—CVS Health Corp. and its Omnicare unit were sued on Tuesday by the U.S. government, which accused them of fraudulently billing Medicare and Medicaid for hundreds of thousands of drugs without valid prescriptions. The U.S. Department of Justice joined two whistleblower lawsuits accusing Omnicare of failing to obtain new prescriptions from…
(Reuters)—A U.S. judge on Friday upheld two patents relating to Amgen Inc,’s blockbuster rheumatoid arthritis drug Enbrel (etanercept), denying a challenge by Novartis AG, which is seeking to launch a biosimilar version. The decision was a relief to investors concerned about a competitive threat to Enbrel, which had U.S. sales of $4.8 billion last year….
WASHINGTON (Reuters)—The U.S. Supreme Court has cast aside pharmaceutical company Allergan Plc.’s unorthodox bid to shield patents from a federal administrative court’s review by transferring them to a Native American tribe. The justices left in place a lower court ruling upholding the authority of a U.S. Patent and Trademark Office tribunal to decide the validity…
(Reuters)—Ohio’s attorney general on Monday said he had filed a lawsuit against UnitedHealth Group Inc’s OptumRx unit, saying the pharmacy benefit manager had overcharged the state nearly $16 million for prescription drugs. Ohio Attorney General Dave Yost’s lawsuit followed a probe into the extent pharmacy benefit managers (PBMs) like OptumRx had engaged in pricing practices…
WASHINGTON/NEW YORK (Reuters)—U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines. Executives from Abbvie Inc., AstraZeneca PLC., Sanofi SA, Pfizer…